journal article·2025-03

Self-amplifying ROS-responsive SN38 prodrug nanoparticles for combined chemotherapy and ferroptosis in cancer treatment

Yu Qin, Na Liu, Fenghui Wang, Zeping Gao, Cong Luo, Chutong Tian, Ken-ichiro Kamei

Carbon· Volume 235
Publisher page

Abstract

No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.

Source: Not provided · Quality: missing

Research context

OpenAlex topics: Ferroptosis and cancer prognosis · Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (47)

Show source-provided references
1. Current cancer epidemiology10.2991/jegh.k.191008.001 ↗
2. Cancer treatment therapies: traditional to modern approaches to combat cancers10.1007/s11033-023-08809-3 ↗
3. The recent developments of camptothecin and its derivatives as potential anti-tumor agents10.1016/j.ejmech.2023.115710 ↗
4. Evolution in medicinal chemistry of E-ring-modified Camptothecin analogs as anticancer agents10.1016/j.ejmech.2013.01.058 ↗
5. Camptothecin (CPT) and its derivatives are known to target topoisomerase I (Top1) as their mechanism of action: did we miss something in CPT analogue molecular targets for treating human disease such as cancer?
6. Advances in delivery of Irinotecan (CPT-11) active metabolite 7-ethyl-10-hydroxycamptothecin10.1016/j.ijpharm.2019.118499 ↗
7. CPT-11 (irinotecan) and 5-fluorouracil: a promising combination for therapy of colorectal cancer10.1016/0959-8049(96)00294-8 ↗
8. Research progress of SN38 drug delivery system in cancer treatment10.2147/IJN.S435407 ↗
9. "Sweet tooth"-oriented SN38 prodrug delivery nanoplatform for targeted gastric cancer therapy
10. Novel prodrugs of SN38 using multiarm poly(ethylene glycol) linkers10.1021/bc700333s ↗
11. Structure modification: a successful tool for prodrug design10.4155/fmc-2022-0309 ↗
12. Responsive nanocarriers as an emerging platform for cascaded delivery of nucleic acids to cancer10.1016/j.addr.2017.03.004 ↗
13. Cancer-associated, stimuli-driven, turn on theranostics for multimodality imaging and therapy10.1002/adma.201606857 ↗
14. Stimulus-responsive self-assembled prodrugs in cancer therapy10.1039/D2SC01003H ↗
15. Self-delivery photo-immune stimulators for photodynamic sensitized tumor immunotherapy10.1021/acsnano.0c06765 ↗
16. High-loading self-assembling peptide nanoparticles as a lipid-free carrier for hydrophobic general anesthetics10.2147/IJN.S315310 ↗
17. Metal-coordinated supramolecular self-assemblies for cancer theranostics10.1002/advs.202101101 ↗
18. Multicomponent carrier-free nanodrugs for cancer treatment10.1039/D2TB02025D ↗
19. Impact of chemotherapy dose intensity on cancer patient outcomes10.6004/jnccn.2009.0009 ↗
20. Synergistic combination chemotherapy using carrier-free celastrol and doxorubicin nanocrystals for overcoming drug resistance10.1039/C8NR02700E ↗
21. Overcoming cancer chemotherapy resistance by the induction of ferroptosis
22. Inducing ferroptosis by traditional medicines: a novel approach to reverse chemoresistance in lung cancer
23. Ferroptosis: molecular mechanisms and health implications10.1038/s41422-020-00441-1 ↗
24. The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis10.1038/s41586-019-1705-2 ↗
25. Application of glutathione depletion in cancer therapy: enhanced ROS-based therapy, ferroptosis, and chemotherapy10.1016/j.biomaterials.2021.121110 ↗
26. PPARα alleviates iron overload-induced ferroptosis in mouse liver10.15252/embr.202052280 ↗
27. Dancing with reactive oxygen species generation and elimination in nanotheranostics for disease treatment10.1016/j.addr.2020.06.006 ↗
28. Signaling pathways and defense mechanisms of ferroptosis10.1111/febs.16059 ↗
29. Tumor-acidity and bioorthogonal chemistry-mediated construction and deconstruction of drug depots for ferroptosis under normoxia and hypoxia10.1016/j.actbio.2022.01.046 ↗
30. Acid-responsive micelles releasing cinnamaldehyde enhance RSL3-induced ferroptosis in tumor cells10.1021/acsbiomaterials.2c00236 ↗
31. Cinnamaldehyde induces apoptosis by ROS-mediated mitochondrial permeability transition in human promyelocytic leukemia HL-60 cells10.1016/S0304-3835(03)00238-6 ↗
32. Cascade of reactive oxygen species generation by polyprodrug for combinational photodynamic therapy10.1016/j.biomaterials.2020.120210 ↗
33. Nano-fenton reactors as a new class of oxidative stress amplifying anticancer therapeutic agents10.1021/acsami.5b12523 ↗
34. Cinnamaldehyde analogues as potential therapeutic agents10.2174/1389557516666160121120744 ↗
35. Thiol reactivity and its impact on the ciliate toxicity of α,β-unsaturated aldehydes, ketones, and esters10.1021/tx100226n ↗
36. N-heterocyclic carbene catalyzed sulfenylation of α,β-unsaturated aldehydes10.1021/acs.orglett.6b02939 ↗
37. A mitochondria-targeting ROS-activated nanoprodrug for self-augmented antitumor oxidation therapy10.1016/j.jconrel.2023.06.004 ↗
38. Probing the superiority of diselenium bond on docetaxel dimeric prodrug nanoassemblies: small roles taking big responsibilities10.1002/smll.202005039 ↗
39. Synthesis and characterization of novel amphiphilic copolymer stearic acid-coupled F127 nanoparticles for nano-technology based drug delivery system10.1016/j.colsurfb.2011.08.010 ↗
40. Protein adsorption and cellular uptake of cerium oxide nanoparticles as a function of zeta potential10.1016/j.biomaterials.2007.07.029 ↗
41. Advance progress in assembly mechanisms of carrier-free nanodrugs for cancer treatment10.3390/molecules28207065 ↗
42. Tailoring carrier-free nanocombo of small-molecule prodrug for combinational cancer therapy10.1016/j.jconrel.2022.10.022 ↗
43. Nanoparticles: cellular uptake and cytotoxicity10.1007/978-94-017-8739-0_5 ↗
44. Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release
45. DNA damage-induced apoptosis10.1038/sj.onc.1207532 ↗
46. Pharmacokinetic and screening studies of the interaction between mononuclear phagocyte system and nanoparticle formulations and colloid forming drugs10.1016/j.ijpharm.2017.04.079 ↗
47. The EPR effect and beyond: strategies to improve tumor targeting and cancer nanomedicine treatment efficacy10.7150/thno.49577 ↗